Aktuelles zu den häufigen Schwindelsyndromen: Diagnostik und Therapie

Zusammenfassung

Die 8 häufigsten Schwindelsyndrome liegen über 70% aller Schwindelpräsentationen zugrunde. Bei den akuten (meist einzeitigen) Schwindelsyndromen sind die akute unilaterale Vestibulopathie und der vestibuläre Schlaganfall von besonderer Bedeutung, bei den episodischen Schwindelerkrankungen der gutartige Lagerungsschwindel, der Morbus Menière und die vestibuläre Migräne und bei chronischem Schwindel die bilaterale Vestibulopathie/Presbyvestibulopathie, der funktionelle Schwindel und der zerebelläre Schwindel. In der letzten Dekade wurden für die häufigsten Schwindelsyndrome international konsentierte diagnostische Kriterien und Krankheitsbezeichnungen erarbeitet, die einfach im klinischen Alltag angewendet werden können. Die diagnostischen Leitlinien beruhen überwiegend auf einer gezielten Anamnese (Beginn, Dauer, Verlauf, Trigger, Begleitsymptome), klinischen Untersuchung und wenigen apparativen Verfahren zur Diagnosesicherung (vor allem mittels Videookulographie und Audiometrie). Die Therapie der häufigen Schwindelsyndrome basiert in der Regel auf einer Kombination aus physikalischen Verfahren (Lagerungsmanöver, multimodales Gleichgewichtstraining) und pharmakologischen Prinzipien (u.a. Kortikosteroide, Antiepileptika, Antidepressiva, Kaliumkanalblockern, plastizitätsfördernde Medikamente). Allerdings fehlt meist eine hochwertige Evidenz aus prospektiven und kontrollierten Studien. In der klinischen Praxis lassen sich die häufigen Schwindelsyndrome oft effektiv behandeln, sodass eine Chronifizierung oder sekundäre Komorbidität (durch Immobilität, Stürze oder psychiatrische Erkrankungen wie Angst oder Depression) vermieden werden kann.

Summary

The 8 most frequent vestibular disorders account for more than 70% of all presentations of vertigo, dizziness, and imbalance. In acute (and mostly non-repetitive) vestibular disorders acute unilateral vestibulopathy and vestibular stroke are most important, in episodic vestibulopathies benign paroxysmal positional vertigo (BPPV), Menière’s disease and vestibular migraine, and in chronic vestibular disorders bilateral vestibulopathy/presbyvestibulopathy, functional dizziness and cerebellar dizziness. In the last decade, internationally consented diagnostic criteria and nomenclature were established for the most frequent vestibular disorders, which can be easily applied in clinical practice. The diagnostic guidelines are based on history taking (including onset, duration, course, triggers, accomanying symptoms), clinical examination, and only a few apparative tests (by videooculography and audiometry) for securing the diagnosis. Treatment of vestibular disorders includes physical training (repositioning maneuvers, multimodal balance training) and pharmacological approaches (e.g., corticosteroids, antiepileptics, antidepressants, potassium-canal-blockers, drugs enhancing neuroplasticity). For most drugs, high-level evidence from prospective controlled trials is lacking. In clinical practice, the most frequent vestibular disorders can be treated effectively, thus avoiding chronicity and secondary comorbidity (by immobility, falls or psychiatric disorders such as anxiety or depression).

Schlüsselwörter

Akute - episodische und chronische Schwindelsyndrome und Gleichgewichtsstörungen - Gangstörungen - Stürze - vestibuläres und okulomotorisches System

Key words

Acute - episodic and chronic vertigo - dizziness and balance disorders - gait disorders - falls - vestibular and ocular motor system

Publication History

Received: 15 December 2020

Accepted: 09 March 2021

Article published online:
19 April 2021

• Literatur

• 1 Strupp M, Brandt T, Dieterich M. Vertigo – Leitsymptom Schwindel. 3. Auflage. Heidelberg: Springer Medizin; 2021: 2021.
• 2 Strupp M. et al. Peripheral, central and functional vertigo syndromes. Nervenarzt 2015; 86: 1573-1584.
• 3 Bisdorff A. et al. Classification of vestibular symptoms: Towards an international classification of vestibular disorders. J Vestib Res 2009; 19 (1–2): 1-13.
• 4 Newman-Toker DE. et al. Spectrum of dizziness visits to US emergency departments: Cross-sectional analysis from a nationally representative sample. Mayo Clin Proc 2008; 83: 765-775.
• 5 Zwergal A, Dieterich M. Vertigo and dizziness in the emergency room. Curr Opin Neurol 2020; 33 (01) : 117-125.
• 6 Royl G, Ploner CJ, Leithner C. Dizziness in the emergency room: Diagnoses and misdiagnoses. Eur Neurol 2011; 66 (05) : 256-263.
• 7 Kuroda R. et al. The TriAGe + score for vertigo or dizziness: A diagnostic model for stroke in the emergency department. J Stroke Cerebrovasc Dis 2017; 26: 1144-1153.
• 8 Zwergal A. et al. A prospective analysis of lesion-symptom relationships in acute vestibular and ocular motor stroke. Front Neurol 2020; 11: 822.
• 9 Paul NL. et al. Transient isolated brainstem symptoms preceding posterior circulation stroke: A population-based study. Lancet Neurol 2013; 12 (01) : 65-71.
• 10 Möhwald. et al. Health-related quality of life and functional impairment in acute vestibular disorders. Eur J Neurol 2020; 27 (10) : 2089-2098.
• 11 Strupp M. et al. Diagnosis and treatment options in vertigo syndromes. Nervenarzt 2015; 86: 1277-1290.
• 12 Zwergal A, Möhwald K, Dieterich M. Vertigo and dizziness in the emergency room. Nervenarzt 2017; 88 (06) : 587-596.
• 13 Cnyrim C. et al. Bedside differentiation of vestibular neuritis from central “vestibular pseudoneuritis”. J Neurol Neurosurg Psychiatry 2008; 79: 458-460.
• 14 Kattah JC. et al. HINTS to diagnose stroke in the acute vestibular syndrome: Three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke 2009; 40: 3504-3510.
• 15 Ahmadi SE. et al. Modern machine-learning can support diagnostic differentiation of central and peripheral acute vestibular disorders. J Neurol 2020; 267 (Suppl 1): 143-152.
• 16 Machner B. et al. Risk of acute brain lesions in dizzy patients presenting to the emergency room: Who needs imaging and who does not?. J Neurol 2020; 267 (Suppl 1): 126-135.
• 17 Choi JY. et al. Central paroxysmal positional nystagmus: Characteristics and possible mechanisms. Neurology 2015; 84: 2238-2246.
• 18 Strupp M, Magnusson M. Acute unilateral vestibulopathy. Neurol Clin 2015; 33: 669-685.
• 19 Rujescu D. et al. Genome-wide association study in vestibular veuritis: involvement of the host factor for HSV-1 replication. Front Neurol 2018; 9: 591.
• 20 Rujescu D. et al. High-risk allele for herpes labialis severity at the IFNL3/ 4 locus is associated with vestibular neuritis. Front Neurol 2020; 11: 570638.
• 21 Zwergal. et al. OP15-8 - Neuroinflammation along the vestibular nerve and nucleus in acute unilateral vestibulopathy. J Vest Res 2018; 28: 53.
• 22 Beck R. et al. The mixed blessing of treating symptoms in acute vestibular failure–evidence from a 4-aminopyridine experiment. Exp Neurol 2014; 261: 638-645.
• 23 Strupp M. et al. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med 2004; 351: 354-361.
• 24 Karlberg ML, Magnusson M. Treatment of acute vestibular neuronitis with glucocorticoids. Otol Neurotol 2011; 32: 1140-1143.
• 25 Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011; 2011 (05) : CD008607.
• 26 Chabbert C. Principles of vestibular pharmacotherapy. Handb Clin Neurol 2016; 137: 207-218.
• 27 Hamann. KF. Special ginkgo extract in cases of vertigo:a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO 2007; 55 (04) 258-263.
• 28 Van Vugt VA. et al. Internet based vestibular rehabilitation with and without physiotherapy support for adults aged 50 and older with a chronic vestibular syndrome in general practice: Three armed randomised controlled trial. BMJ 2019; 367: l5922.
• 29 Tarnutzer AA. et al. ED misdiagnosis of cerebrovascular events in the era of modern neuroimaging: A meta-analysis. Neurology 2017; 88: 1468-1477.
• 30 Atzema CL. et al. Outcomes among patients discharged from the emergency department with a diagnosis of peripheral vertigo. Ann Neurol 2016; 79: 32-41.
• 31 Saber Tehrani AS. et al. Small strokes causing severe vertigo: Frequency of false-negative MRIs and nonlacunar mechanisms. Neurology 2014; 83 (02) : 169-173.
• 32 Machner B. et al What guides decision-making on intravenous thrombolysis in acute vestibular syndrome and suspected ischemic stroke in the posterior circulation? J Neurol 2021; 268 (01) 249-264.
• 33 Schubeck F. et al. Langzeitprognose von Patienten nach Schlaganfall mit Leitsymptom Schwindel. DGN Kongress; , 2020
• 34 Von Brevern M. et al. Benign paroxysmal positional vertigo: Diagnostic criteria. J Vestib Res 2015; 25: 105-117.
• 35 Hilton MP, Pinder DK. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo. Cochrane Database Syst Rev 2014; 12: (CD003162).
• 36 Strupp M. et al. Benign paroxysmal positional vertigo: The “Sémont PLUS maneuver” is more effective than the Sémont maneuver – A prospective multinational randomized single-blinded trial. EAN Congress. 2020 2020; EPR1224.
• 37 Bremova T. et al. Ocular VEMPs indicate repositioning of otoconia to the utricle after successful liberatory maneuvers in benign paroxysmal positioning vertigo. Acta Otolaryngol 2013; 133 (12) : 1297-1303.
• 38 Brandt T. et al. Benign paroxysmal positioning vertigo: A long-term follow-up (6-17 years) of 125 patients. Acta Otolaryngol 2006; 126 (02) : 160-163.
• 39 AlGarni MA. et al. Association of benign paroxysmal positional vertigo with vitamin D deficiency: A systematic review and meta-analysis. Eur Arch Otorhinolaryngol 2018; 275: 2705-2711.
• 40 Jeong SH. et al. Prevention of benign paroxysmal positional vertigo with vitamin D supplementation: A randomized trial. Neurology 2020; 95 (09) : e1117-e1125.
• 41 Lopez-Escamez JA. et al. Diagnostic criteria for Meniere’s disease. J Vestib Res 2015; 25: 1-7.
• 42 Gürkov R. et al. In vivo visualization of endolyphatic hydrops in patients with Meniere’s disease: Correlation with audiovestibular function. Eur Arch Otorhinolaryngol 2011; 268: 1743-1748.
• 43 Plontke SK, Gürkov R. Menière’s Disease. . Laryngorhinootologie: 2015. 94. 530-554.
• 44 Dlugaiczyk J, Habs M, Dieterich M. Vestibular evoked myogenic potentials in vestibular migraine and Menière’s disease: CVEMPs make the difference. J Neurol 2020; 267 (Suppl 1): 169-180.
• 45 Zwergal A, Strupp M, Brandt T. Advances in pharmacotherapy of vestibular and ocular motor disorders. Expert Opin Pharmacother 2019; 20 (10) : 1267-1276.
• 46 Garduno-Anaya MA. et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Meniere’s disease: A two-year prospective. Placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005; 133 (02) : 285-294.
• 47 Patel M. et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière’s disease: A randomised. Double-blind, comparative effectiveness trial. Lancet 2016; 388 (10061): 2753-2762.
• 48 Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere’s disease and vestibular vertigo. Eur Arch Otorhinolaryngol 2014; 271 (05) : 887-897.
• 49 Adrion C. et al. Efficacy and safety of betahistine treatment in patients with Meniere’s disease: Primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 2016; 352: h6816.
• 50 Ihler F. et al. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in Guinea pigs in vivo. PLoS One 2012; 7 (06) : e39086.
• 51 Lempert T. et al. Vestibular migraine: Diagnostic criteria. J Vestib Res 2012; 22: 167-172.
• 52 Dieterich M, Obermann M, Celebisoy N. Vestibular migraine: The most frequent entity of episodic vertigo. J Neurol 2016; 263 (Suppl 1): S82-89.
• 53 Von Brevern M. et al. Acute migrainous vertigo: Clinical and oculographic findings. Brain 2005; 128 (Pt 2): 365-374.
• 54 Chang TP. et al. The bucket test differentiates patients with MRI confirmed brainstem/cerebellar lesions from patients having migraine and dizziness alone. BMC Neurol 2019; 19 (01) : 219.
• 55 Radtke A. et al. Vestibular migraine: Long-term follow-up of clinical symptoms and vestibulo-cochlear findings. Neurology 2012; 79 (15) : 1607-1614.
• 56 Maldonado FM. et al. Pharmacological treatment for the prevention of vestibular migraine. Cochrane Database of Systematic Reviews 2015; 06: CD010600.
• 57 Strupp M. et al. Bilateral vestibulopathy: Diagnostic criteria Consensus document of the Classification Committee of the Barany Society. J Vestib Res 2017; 27 (04) : 177-189.
• 58 Zingler VC. et al. Causative factors and epidemiology of bilateral vestibulopathy in 255 patients. Ann Neurol 2007; 61 (06) : 524-532
• 59 Rafehi H. et al. Bioinformatics-based identification of expanded repeats: A non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am J Hum Genet 2019; 105 (01) : 151-165.
• 60 Gisatulin M. et al. Clinical spectrum of the pentanucleotide repeat expansion in the RFC1 gene in ataxia syndromes. Neurology 2020; 95 (21) : e2912-e2923.
• 61 Zingler VC. et al. Follow-up of vestibular function in bilateral vestibulopathy. J Neurol Neurosurg Psychiatry 2007; 79: 284-288.
• 62 Meldrum D, Jahn K. Gaze stabilisation exercises in vestibular rehabilitation: Review of the evidence and recent clinical advances. J Neurol 2019; 266 (Suppl 1): 11-18.
• 63 Wuehr M, Decker J, Schniepp R. Noisy galvanic vestibular stimulation: An emerging treatment option for bilateral vestibulopathy. J Neurol 2017; 264 (Suppl 1): 81-86.
• 64 Schniepp R. et al. Noisy vestibular stimulation improves vestibulospinal function in patients with bilateral vestibulopathy. J Neurol 2018; 265 (Suppl 1): 57-62.
• 65 Van De Berg R. et al. The vestibular implant: Opinion statement on implantation criteria for research. J Vestib Res 2020; 30 (03) : 213-223.
• 66 Zwergal A. et al. Cerebellar dizziness and vertigo: etiologies, diagnostic assessment, and treatment. Semin Neurol 2020; 40 (01) : 87-96.
• 67 Feil K. et al. What Is behind cerebellar vertigo and dizziness?. Cerebellum 2019; 18 (03) : 320-332.
• 68 Strupp M. et al. Aminopyridines for the treatment of neurologic disorders. Neurol Clin Pract 2017; 7 (01) : 65-76.
• 69 Strupp M. et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study. Neurology 2003; 61 (02) : 165-170.
• 70 Feil K. et al. Effect of chlorzoxazone in patients with downbeat nystagmus: A pilot trial. Neurology 2013; 81 (13) : 1152-1158.
• 71 Schniepp R. et al. 4-Aminopyridine and cerebellar gait: A retrospective case series. J Neurol 2012; 259 (11) : 2491-2493.
• 72 Strupp M. et al. Effects of acetyl-DL-leucine in patients with cerebellar ataxia: A case series. J Neurol 2013; 260 (10) : 2556-2561.
• 73 Habs M. et al. Primary or secondary chronic functional dizziness: Does it make a difference? A DizzyReg study in 356 patients. J Neurol 2020; 267 (Suppl 1): 212-222.
• 74 Staab JP. et al. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Barany Society. J Vestib Res 2017; 27 (04) : 191-208.
• 75 Wuehr M. et al. Inadequate interaction between open- and closed-loop postural control in phobic postural vertigo. J Neurol 2013; 260 (05) : 1314-1323.
• 76 Dieterich M, Staab JP. Functional dizziness: From phobic postural vertigo and chronic subjective dizziness to persistent postural-perceptual dizziness. Curr Opin Neurol 2018; 139: 447-468.
• 77 Popp P. et al. Cortical alterations in phobic postural vertigo – a multimodal imaging approach. Ann Clin Transl Neurol 2018; 5 (06) : 717-729.
• 78 Holmberg J. et al. One-year follow-up of cognitive behavioral therapy for phobic postural vertigo. J Neurol 2007; 254: 1189-1192.
• 79 Huppert D. et al. Phobic postural vertigo – a long-term follow-up (5 to 15 years) of 106 patients. J Neurol 2005; 252 (05) : 564-569.
• 80 Agrawal Y. et al. Presbyvestibulopathy: Diagnostic criteria consensus document of the classification committee of the Bárány Society. J Vestib Res 2019; 29 (04) : 161-170.
• 81 Cnyrim. et al. Central compensation of deviated subjective visual vertical in Wallenberg’s syndrome. J Neurol Neurosurg Psychiatry 2007; 78 (05) : 527-528.
• 82 Claassen J. et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus–effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 2013; 84 (12) : 1392-1399.